OtherAbsorption, Distribution, Metabolism, and Excretion
Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
David L. Bourdet, John B. Pritchard and Dhiren R. Thakker
Journal of Pharmacology and Experimental Therapeutics September 1, 2005, DOI: https://doi.org/10.1124/jpet.105.091223
David L. Bourdet
John B. Pritchard
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherAbsorption, Distribution, Metabolism, and Excretion
Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
David L. Bourdet, John B. Pritchard and Dhiren R. Thakker
Journal of Pharmacology and Experimental Therapeutics September 1, 2005, DOI: https://doi.org/10.1124/jpet.105.091223
OtherAbsorption, Distribution, Metabolism, and Excretion
Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
David L. Bourdet, John B. Pritchard and Dhiren R. Thakker
Journal of Pharmacology and Experimental Therapeutics September 1, 2005, DOI: https://doi.org/10.1124/jpet.105.091223
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement